StockData

Alaunos Therapeutics vs Talphera

TCRT and TLPH side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How TCRT and TLPH compare

Talphera is the larger company, worth 9.9 times as much as Alaunos Therapeutics ($41.6M against $4.2M).

Alaunos Therapeutics grew revenue faster over the last twelve months (−50.0% versus −96.3% for Talphera).

Alaunos Therapeutics keeps more of each dollar of sales as profit, with a net margin of −133667% compared with −1507600% at Talphera.

Talphera scores higher on the StockData Score (5 against 4 for Alaunos Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricTCRTTLPH
Size and price
Market cap$4.2M$41.6M
Share price$1.66$0.801
Change, 1 year−44.1%−35.9%
Change, 5 years−99.2%−93.8%
Beta (5Y)−2.451.28
Employees112
StockData Score
Total score45 (better)
Valuation score00
Growth score00
Performance score00
Health score45 (better)
Dividend score00
Valuation
P/S1406× (better)41566×
P/B6.5×2.9× (better)
Growth
Revenue growth (TTM)−50.0% (better)−96.3%
Revenue growth, 5Y average–−65.1%
Profitability
Operating margin−135267% (better)−1474700%
Net margin−133667% (better)−1507600%
Return on equity−186%−143% (better)
Return on invested capital−489%–
Financial health
Debt / equity0.000.00
Current ratio0.774.29 (better)
Altman Z-score−861.74−24.17 (better)
Piotroski F-score35 (better)
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions3.6%54.4%
Held by insiders69.8%46.8%
Insider net buying, 12 months–$304K
Short interest, % of float24.0%4.4%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.